Gastrointestinal Therapeutics Market Trends Are Creating New Opportunities For Industry Leaders
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Gastrointestinal Therapeutics Market Revenue Growth Supported By A CAGR Of 55.21% Through 2030
The gastrointestinal therapeutics market has experienced robust expansion in recent years, with its value projected to increase from $42.3 billion in 2025 to $44.72 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historic period’s growth has been driven by factors such as the constrained availability of biologics and advanced gastrointestinal treatments, a rising occurrence of acid reflux and ulcers, a dependency on hospital and clinic-based care, heightened awareness of digestive health, and the prevailing influence of conventional over-the-counter antacids and laxatives.
The gastrointestinal therapeutics market is projected to experience robust expansion over the coming years, with an anticipated value of $55.21 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.4%. This forecasted rise is driven by advancements in targeted biologics and immunotherapies, the growing presence of ambulatory surgical centers and diagnostic labs, increased use of oral and intravenous delivery methods, greater penetration of online pharmacies, and new developments in probiotics and digestive enzyme products. Key trends shaping this period include the growing frequency of gastrointestinal conditions, a higher adoption rate of biologics and novel therapies, a broader availability of over-the-counter treatments, a stronger emphasis on personalized care for gastrointestinal issues, and the expanding role of online and retail pharmacy channels.
Download A Free Sample Report For Comprehensive Market Insights:
Gastrointestinal Therapeutics Market Growth Drivers And Industry Catalysts
A surge in inflammatory bowel diseases is anticipated to accelerate the expansion of the gastrointestinal therapeutics market in the coming period. These conditions, such as Crohn’s disease and ulcerative colitis, are chronic disorders that lead to inflammation within the digestive tract. Their growing prevalence is linked to genetic factors that trigger an abnormal immune reaction against gut microbes. Treatment options in gastrointestinal therapeutics aim to manage these diseases by addressing the root inflammation, supporting digestive processes, and lessening symptoms to enhance patient well-being. Data from December 2023, released by the UK-based non-profit IBD Registry, showed that more than 5,300 people with these conditions were added to their registry, reflecting a rise of over 3,000 individuals compared to the previous year. Consequently, this uptick in inflammatory bowel disease cases is fueling market growth for gastrointestinal therapeutics.
Gastrointestinal Therapeutics Market Segment Analysis And Revenue Opportunities
The gastrointestinal therapeutics market covered in this report is segmented –
1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics
Gastrointestinal Therapeutics Market Trends Influencing Long-Term Demand
Major players in the gastrointestinal therapeutics market are prioritizing the development of advanced treatment options, including sustained-release (SR) fixed-dose combination capsules, which are designed to boost patient adherence and optimize therapeutic outcomes. These capsules are oral medications that steadily deliver multiple active ingredients over a prolonged period, ensuring stable drug levels in the body and minimizing the need for frequent dosing. A notable example occurred in June 2024 when Akums Drugs and Pharmaceuticals Limited, a pharmaceutical manufacturing company based in India, introduced rabeprazole + levosulpiride SR capsules for managing gastrointestinal disorders within the country. This innovative formulation pairs rabeprazole, a proton pump inhibitor that reduces stomach acid production, with levosulpiride, a prokinetic agent that enhances gut motility. By working together, these components provide significant relief from symptoms like heartburn, acid reflux, bloating, and indigestion. This combination is frequently prescribed to address conditions such as gastroesophageal reflux disease, peptic ulcers, and various other gastrointestinal (GI) issues.
Gastrointestinal Therapeutics Market Leading Players Shaping Industry Direction
Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation
Access The Complete Gastrointestinal Therapeutics Market Report:
Gastrointestinal Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
